Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
January 22, 2025Pamplona/MadridIn recruitmentEarly phase
CA209-8TT Trial for long-term follow-up of cancer survivors who have participated in nivolumab research trials
The purpose of this study is to collect information on the long-term safety and survival of participants with different tumor types who will receive nivolumab, or who have completed treatment and are now being followed or have completed follow-up in a Bristol-Myers Squibb (BMS) clinical trial. -
January 21, 2025Pamplona/MadridIn recruitmentEarly phase
AMX-818-001 Clinical trial of AMX 818 alone and with pembrolizumab in participants with HER2-expressing locally advanced or metastatic cancers
The purpose of this clinical trial is to evaluate whether the AMX-818 trial drug, alone or in combination with pembrolizumab at different doses, is safe and effective in treating human cancers that produce a protein called HER2 and to learn how your body processes and reacts to the trial drug. -
December 30, 2024PamplonaIn recruitmentEarly phase
LCB-2401-001 Phase 1, open-label, dose-finding clinical trial of nilk-2401, a bispecific, ceacam5 x cd47 Antibody, as a single agent and in combination with anti-pd-1 Antibody, in patients with ceacam5-expressing solid cancers.
The aim of this research is to evaluate whether NILK-2401 as a single agent has beneficial effects and is safe in patients with these cancers. -
December 30, 2024PamplonaIn recruitment
KT-US-679-0788 The purpose of this study is to find out whether the experimental treatment, anito-cel, is safe and effective for the treatment of their relapsed or refractory multiple myeloma compared to the reference treatment.
The purpose of this study is to find out whether the experimental treatment, anito-cel, is safe and effective for the treatment of their relapsed or refractory multiple myeloma compared to the reference treatment. -
December 30, 2024PamplonaIn recruitmentEarly phase
KQB198-101 [SP]
The aim is to test an investigational (experimental) drug called KQB198 that could help stop the growth of cancer cells. -
December 19, 2024Pamplona/MadridIn recruitment
IMC-F106C-301 Trial of BMI-F106C plus nivolumab vs. nivolumab in HLA A*02:01-positive participants with previously untreated advanced melanoma.
The main objective of this study is to know whether the study drug (IMC-F106C at two different doses) in combination with the reference treatment (nivolumab) is better than nivolumab alone in keeping tumors from increasing or decreasing in size. -
December 16, 2024Pamplona/MadridIn recruitment
EIK1003-001 Phase I/II clinical trial of the selective PARP1 inhibitor, IMP1734, in participants with advanced solid tumors.
The main objective of this study is to evaluate the extent to which IMP1734 is tolerated, alone and in combination with other anticancer drugs, as a treatment for patients with ovarian, breast, prostate and pancreatic cancer. -
December 16, 2024PamplonaIn recruitment
CCTL019A2205B Long-term follow-up of patients exposed to lentiviral vector-based CART cell therapy.
This is a long-term follow-up trial sponsored (funded) by the pharmaceutical company Novartis. If you agree to participate in this study, you will be followed for up to 15 years after your last infusion of your CART cells to assess both the safety and risk of late safety problems suspected to be related to the treatment of your CART cells, or certain laboratory parameters, and efficacy including the status of your primary malignancy. -
December 11, 2024Pamplona/MadridIn recruitment
SPI-BEL-301 Trial of Beleodaq-CHOP or Folotyn-COP with the CHOP dosing regimen in monotherapy in patients with newly diagnosed peripheral T lymphocyte lymphoma.
Part 1 of this study is mainly aimed at finding out what is the best dose of belinostat and pralatrexate together for administration together with another drug combination in Part 2 of the study. The main objective of Part 2 of the study is to evaluate the safety and efficacy of belinostat together with CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine] and prednisone), and the safety and efficacy of pralatrexate together with COP (CHOP without hydroxydaunorubicin [... -
December 5, 2024MadridIn recruitmentEarly phase
MS201924_0002 Tuvusertib combinado con niraparib o lartesertib en participantes con cáncer epitelial de ovario. [SP]
El principal obejtivo es analizar sus muestras, junto con su información personal y las imágenes obtenidas como parte del ensayo principal para estudiar los genes, averiguar cómo se relacionan estos genes y las variaciones genéticas con la manera en que actúa el tratamiento del ensayo o saber más sobre su enfermedad y la respuesta al tratamiento.